PCVX
NASDAQ HealthcareVaxcyte, Inc. - Common Stock
Biotechnology
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
�� 市场数据
| 价格 | $62.35 |
|---|---|
| 成交量 | 1,115,212 |
| 市值 | 9.05B |
| 贝塔系数 | 1.390 |
| RSI（14日） | 77.3 超买 |
| 200日均线 | $44.96 |
| 50日均线 | $57.86 |
| 52周最高 | $65.00 |
| 52周最低 | $28.09 |
| Forward P/E | -8.55 |
| Price / Book | 3.04 |
🎯 投资策略评分
PCVX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (71/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (12/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 PCVX in your text
粘贴任何文章、记录或帖子 — 工具将提取 PCVX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.